JP2020533368A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533368A5 JP2020533368A5 JP2020515026A JP2020515026A JP2020533368A5 JP 2020533368 A5 JP2020533368 A5 JP 2020533368A5 JP 2020515026 A JP2020515026 A JP 2020515026A JP 2020515026 A JP2020515026 A JP 2020515026A JP 2020533368 A5 JP2020533368 A5 JP 2020533368A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- bladder
- abx196
- compound abx196
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- VITDDUXZOHEQMU-BYSUZVQFSA-N N-[(2S,3S,4R)-1-[(2S,3R,4S,5R,6R)-6-(acetamidomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihydroxyoctadecan-2-yl]tetracosanamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CNC(C)=O)[C@H](O)[C@H](O)[C@H]1O VITDDUXZOHEQMU-BYSUZVQFSA-N 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 11
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 7
- 206010005003 Bladder cancer Diseases 0.000 claims 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 claims 2
- 201000001528 bladder urothelial carcinoma Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 206010004992 Bladder adenocarcinoma stage unspecified Diseases 0.000 claims 1
- 206010005081 Bladder squamous cell carcinoma stage unspecified Diseases 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000006587 bladder adenocarcinoma Diseases 0.000 claims 1
- 201000006598 bladder squamous cell carcinoma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17306182 | 2017-09-13 | ||
| EP17306182.1 | 2017-09-13 | ||
| PCT/EP2018/074778 WO2019053142A1 (en) | 2017-09-13 | 2018-09-13 | ABX196 FOR USE IN THE TREATMENT OF BLADDER CANCER |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020533368A JP2020533368A (ja) | 2020-11-19 |
| JP2020533368A5 true JP2020533368A5 (enExample) | 2021-09-30 |
| JP7214718B2 JP7214718B2 (ja) | 2023-01-30 |
Family
ID=60001797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020515026A Active JP7214718B2 (ja) | 2017-09-13 | 2018-09-13 | 膀胱癌の治療に使用するためのａｂｘ１９６ |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11266667B2 (enExample) |
| EP (1) | EP3681512B1 (enExample) |
| JP (1) | JP7214718B2 (enExample) |
| KR (1) | KR102706165B1 (enExample) |
| CN (1) | CN111182907B (enExample) |
| AU (1) | AU2018332046B2 (enExample) |
| BR (1) | BR112020004778A2 (enExample) |
| CA (1) | CA3075443A1 (enExample) |
| CU (1) | CU20200020A7 (enExample) |
| DK (1) | DK3681512T3 (enExample) |
| ES (1) | ES2893549T3 (enExample) |
| HR (1) | HRP20211351T1 (enExample) |
| IL (1) | IL273054B2 (enExample) |
| MX (1) | MX394216B (enExample) |
| PL (1) | PL3681512T3 (enExample) |
| PT (1) | PT3681512T (enExample) |
| WO (1) | WO2019053142A1 (enExample) |
| ZA (1) | ZA202001435B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022187141A1 (en) | 2021-03-01 | 2022-09-09 | Deciduous Therapeutics | Compounds for activating invariant natural killer t-cells and methods of use in eliminating inflammatory senescent cells |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008350531B2 (en) * | 2007-12-05 | 2014-01-23 | Abivax | Use of glycosylceramides for enhancing the immune response to antigens |
| CN102215864A (zh) * | 2008-10-08 | 2011-10-12 | 威蒂赛尔公司 | 用于抗流感的疫苗组合物 |
| US9181292B2 (en) * | 2011-01-05 | 2015-11-10 | Pi-Hui Liang | Methods for preparation of glycosphingolipids and uses thereof |
| RU2770432C2 (ru) * | 2016-09-14 | 2022-04-18 | Абивакс | Комбинации для лечения рака, включающие abx196 |
-
2018
- 2018-09-13 DK DK18765477.7T patent/DK3681512T3/da active
- 2018-09-13 CN CN201880064390.5A patent/CN111182907B/zh active Active
- 2018-09-13 BR BR112020004778-3A patent/BR112020004778A2/pt active Search and Examination
- 2018-09-13 ES ES18765477T patent/ES2893549T3/es active Active
- 2018-09-13 HR HRP20211351TT patent/HRP20211351T1/hr unknown
- 2018-09-13 PT PT18765477T patent/PT3681512T/pt unknown
- 2018-09-13 WO PCT/EP2018/074778 patent/WO2019053142A1/en not_active Ceased
- 2018-09-13 JP JP2020515026A patent/JP7214718B2/ja active Active
- 2018-09-13 CU CU2020000020A patent/CU20200020A7/es unknown
- 2018-09-13 MX MX2020002812A patent/MX394216B/es unknown
- 2018-09-13 US US16/647,379 patent/US11266667B2/en active Active
- 2018-09-13 KR KR1020207007414A patent/KR102706165B1/ko active Active
- 2018-09-13 PL PL18765477T patent/PL3681512T3/pl unknown
- 2018-09-13 AU AU2018332046A patent/AU2018332046B2/en active Active
- 2018-09-13 EP EP18765477.7A patent/EP3681512B1/en active Active
- 2018-09-13 CA CA3075443A patent/CA3075443A1/en active Pending
-
2020
- 2020-03-04 IL IL273054A patent/IL273054B2/en unknown
- 2020-03-06 ZA ZA2020/01435A patent/ZA202001435B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022121594A5 (enExample) | ||
| JP2022009090A5 (enExample) | ||
| Zhang et al. | Advancements of radiotherapy for recurrent head and neck cancer in modern era | |
| JP2024133474A5 (enExample) | ||
| JP2016528162A5 (enExample) | ||
| JP2016536286A5 (enExample) | ||
| JP2022153392A5 (enExample) | ||
| JP2022124458A5 (enExample) | ||
| JP2022031331A (ja) | 空間配置が変化した組換えインターフェロンを用いる腫瘍治療の方法 | |
| JP2016501221A5 (enExample) | ||
| RU2018105655A (ru) | Комбинированная терапия с применением липосомального иринотекана и ингибитора parp для лечения рака | |
| JP2017031160A5 (enExample) | ||
| RU2019133284A (ru) | Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства | |
| JP2015508103A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| RU2020120593A (ru) | Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом | |
| JP2020514292A5 (enExample) | ||
| JP2020523354A5 (enExample) | ||
| JP2018062523A5 (enExample) | ||
| JPWO2021214019A5 (enExample) | ||
| JP2014530181A5 (enExample) | ||
| RU2017124371A (ru) | Комбинация производного 6-оксо-1,6-дигидро-пиридазина, обладающего противораковой активностью, с производным хиназолина | |
| CN110494131A (zh) | 精胺及其衍生物在制备抗肿瘤药物中的应用 | |
| CN101773499A (zh) | 延胡索乙素的新用途 | |
| JP2020533368A5 (enExample) |